Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;52(2):301-303.
doi: 10.1038/bmt.2016.261. Epub 2016 Nov 21.

Low day +100 serum epidermal growth factor levels are associated with acute GvHD after allogeneic hematopoietic cell transplantation

F He  1 , M R Verneris  2 , S Cooley  1 , B R Blazar  2 , M L MacMillan  2 , L F Newell  3 , A Panoskaltsis-Mortari  2 , T DeFor  1 , D J Weisdorf  1 , S G Holtan  1
Affiliations

Low day +100 serum epidermal growth factor levels are associated with acute GvHD after allogeneic hematopoietic cell transplantation

F He et al. Bone Marrow Transplant. 2017 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
EGF associations with aGvHD severity and location, response to treatment of aGvHD and immunosuppression. (a) EGF levels in relation to severity of aGvHD grades I–IV. (b) EGF levels in no aGvHD, non-upper GI aGvHD and upper GI aGvHD. (c) EGF levels and response to treatment of aGvHD. CR, complete response; NR, no response; PR, partial response (P>0.05). (d) EGF levels and concurrent immunosuppressive medications.
Figure 2
Figure 2
(a) Kaplan–Meier estimate of survival based upon day +100 epidermal growth factor (EGF) levels and platelet count (×109/L). (b) ROC curve for conventional risk factors for a 2-year survival (age plus acute GvHD), conventional factors plus low EGF, and conventional factors plus composite of low EGF and low platelets.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kennedy MS, Deeg HJ, Storb R, Doney K, Sullivan KM, Witherspoon RP, et al. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. Am J Med. 1985;78(6 Pt 1):978–983. - PubMed
    1. Bacigalupo A, van Lint MT, Frassoni F, Podesta’ M, Veneziano G, Avanzi G, et al. High dose bolus methylprednisolone for the treatment of acute graft versus host disease. Blut. 1983;46:125–132. - PubMed
    1. Wong WM, Wright NA. Epidermal growth factor, epidermal growth factor receptors, intestinal growth, and adaptation. JPEN J Parenter Enteral Nutr. 1999;23(5 Suppl):S83–S88. - PubMed
    1. Holtan SG, Verneris MR, Schultz KR, Newell LF, Meyers G, He F, et al. Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biol Blood Marrow Transplant. 2015;21:1029–1036. - PMC - PubMed
    1. Oka Y, Orth DN. Human plasma epidermal growth factor/beta-urogastrone is associated with blood platelets. J Clin Invest. 1983;72:249–259. - PMC - PubMed

Publication types